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Abstract
Mucolipidosis II (ML II), also called I-cell disease, is a unique lysosomal storage disease caused by deficient activity of the
enzyme N-acetylglucosamine-1-phosphotransferase, which leads to a failure to internalize enzymes into lysosomes. We
report on a colony of domestic shorthair cats with ML II that was established from a half-sibling male of an affected cat.
Ten male and 9 female kittens out of 89 kittens in 26 litters born to clinically normal parents were affected; this is consistent
with an autosomal recessive mode of inheritance. The activities of three lysosomal enzymes from affected kittens, compared
to normal adult control cats, were high in serum (11–73 times normal) but low in cultured fibroblasts (9–56% of normal
range) that contained inclusion bodies (I-cells), reflecting the unique enzyme defect in ML II. Serum lysosomal enzyme
activities of adult obligate carriers were intermediate between normal and affected values. Clinical features in affected kittens
were observed from birth and included failure to thrive, behavioral dullness, facial dysmorphia, and ataxia. Radiographic
lesions included metaphyseal flaring, radial bowing, joint laxity, and vertebral fusion. In contrast to human ML II, diffuse
retinal degeneration leading to blindness by 4 months of age was seen in affected kittens. All clinical signs were progressive
and euthanasia or death invariably occurred within the first few days to 7 months of life, often due to upper respiratory
disease or cardiac failure. The clinical and radiographic features, lysosomal enzyme activities, and mode of inheritance are
homologous with ML II in humans. Feline ML II is currently the only animal model in which to study the pathogenesis of
and therapeutic interventions for this unique storage disease.
Mucolipidosis II (ML II, OMIM 252500; McKusick 2000) in
humans, also known as I-cell disease, is a rare, unique, re-
cessively inherited lysosomal storage disease (LSD) (Korn-
feld and Sly 2000). Although clinically similar to several
forms of mucopolysaccharidosis (MPS), it is biochemically
distinct, as it results from a problem in trafficking of enzymes
to the lysosomes rather than deficiency of a specific lyso-
somal hydrolase. ML II is caused by deficient activity of
N-acetylglucosamine-1-phosphotransferase (GlcNAc-phos-
photransferase, EC 2.7.8.17) in the Golgi apparatus, the first
of two enzymes responsible for binding phosphate to man-
nose residues of lysosomal acid hydrolases (Canfield et al.
1998; Hasilik et al. 1981; Okada et al. 1985; Waheed et al.
1982). The resulting mannose-6-phosphate moiety of these
hydrolases normally binds to specific receptors that direct
the enzymes to the lysosomes. In ML II, these enzymes are
not trafficked properly to the lysosomes and instead leak into
the extracellular compartment. Thus affected lysosomes are
secondarily deficient in most acid hydrolases (Lightbody et
al. 1971) and are unable to degrade some macromolecules. In
contrast, plasma levels of lysosomal hydrolases are high
(Leroy et al. 1971; Sprigz et al. 1978). The resulting lysosomal
storage, first reported in cultured fibroblasts (Hanai et al.
1971; Leroy and DeMars 1967), is seen as cytoplasmic in-
clusion bodies, particularly in the mesenchymal cells, hence
the term I-cell (inclusion cell) disease (Leroy et al. 1971;
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Tondeur et al. 1971). Because of the clinical similarities
to MPS and sphingolipidosis, the disease is referred to as
mucolipidosis II (Kaufmann et al. 1970), although there is
apparently no excessive lipid storage in lysosomes (Hanai et
al. 1971), and the precise nature of the accumulated materials
remains elusive (Kornfeld and Sly 2000).
Human ML II is characterized by coarse facial features,
severe skeletal abnormalities, psychomotor retardation,
failure to thrive, growth retardation, and death within the
first few years of life (Kornfeld and Sly 2000; Leroy and
DeMars 1967; Leroy et al. 1969). One domestic shorthair cat
with ML II has been described (Bosshard et al. 1996; Hubler
et al. 1996). In this article we define the establishment of
a colony of cats with ML II from a carrier male cat related to
the original affected cat, characterize the clinical and
biochemical features and the mode of inheritance, and docu-
ment the close homology to ML II in humans.
Materials and Methods
Animals
One male (3739) and two female (3740 and 3741)
phenotypically normal half siblings of the original affected
domestic shorthair cat with ML II found in Switzerland
(Bosshard et al. 1996; Hubler et al. 1996) were donated to the
University of Pennsylvania. The male half sibling of the
affected cat (no. 3739) was bred to his two female littermates
as well as outcrossed to normal female domestic shorthair
cats. Phenotypically normal F1 females were backcrossed to
cat 3739. F1 females that produced affected kittens were also
bred to phenotypically normal F1 and F2 males. Breeding
records, physical examination findings, body weights, and
time and cause of death were recorded for all offspring. Cats
were raised and studied according to National Institutes of
Health (NIH) and U.S. Department of Agriculture (USDA)
guidelines for the care and use of laboratory animals in
research. The animals were provided ad libitum food and
water and housed with 12-hour light cycles at 218C with 12–
15 air exchanges per hour. Affected and related cats that did
not die a natural death were euthanized at various ages using
sodium phenobarbital in accordance with the guidelines of
the American Veterinary Medical Association.
Lysosomal Enzyme Assays
The original affected cat’s diagnosis was based on low
leukocyte GlcNAc-phosphotransferase activity, severely in-
creased serum activity of several lysosomal enzymes, and
clinicopathologic findings (Bosshard et al. 1996; Hubler et al.
1996). Because the substrate for GlcNAc-phosphotransfer-
ase activity is not readily available and the molecular basis of
feline ML II remains undefined, the ML II status of the cats
in this article was determined by measuring the activity of
several lysosomal enzymes in serum, as well as by the
characteristic clinical signs and the typical cytoplasmic
inclusions in the mesenchymal cells, as has been done in
humans (Tondeur et al. 1971). Blood was collected via
jugular venipuncture and serum was separated by centrifu-
gation and stored frozen at 208C until assayed. In addition,
fibroblast cultures were aseptically prepared from tissue
biopsies from the linea alba or pericardium of affected and
normal cats at postmortem evaluation. Fibroblasts were
grown (RPMI 1640 medium, Invitrogen Corp., Gibco,
Grand Islands, NY) in T175 flasks, and at confluency, the
fibroblasts were trypsinized, washed (Hanks’ balanced salt
solution without calcium and magnesium, Cellgro, Media-
tech, Herdon, VA), and frozen at 1308C until analysis
(Verma and Babu 1995). a-mannosidase (EC 3.2.1.24), b-
glucuronidase (EC 3.2.1.31), and a-fucosidase (EC 3.2.1.51)
activities were measured in serum and fibroblasts using the
artificial substrate 4-methylumbelliferyl b-D-glucuronide
(Sigma, St. Louis, MO), and activities were expressed as
nmol/h/ml serum or mg protein as described (Bosshard et
al. 1996; Glaser and Sly 1973; Wegner and Williams 1991).
Protein concentrations were determined by the method of
Lowry (Lowry et al. 1951).
Clinical and Laboratory Evaluations
Clinical, neurologic, ophthalmologic, and radiologic exami-
nations were performed in a routine manner. Blood for
complete blood cell counts (CBC) and serum chemistry
determinations, as well as urine samples for urinalysis and
a toluidine blue spot test (MPS spot test) for glycosamino-
glycan (GAG) detection (Berry and Spinanger 1960) were
obtained. Tissue samples for light microscopy were collected
from cats at postmortem examination, fixed in buffered 10%
formalin, paraffin-embedded, sectioned, and stained with
hematoxylin and eosin. All clinical, laboratory, biochemical,
and pathologic results of affected cats were compared to
related and unrelated age-matched control cats.
Results
Breeding Studies and Pedigree Analysis
Breeding between a phenotypically normal male cat (no.
3739), a half sibling of the original cat with ML II, and his
two phenotypically normal female siblings as well as to other
unrelated female cats did not produce any phenotypically
affected kittens. However, breeding between male 3739 and
his daughters (F1 females) and between F1 or F2 males and
F1 females produced phenotypically normal and affected
kittens. One F3 female was bred to an F1 male. When
outcrossing cats that produced affected kittens to unrelated
normal cats, all kittens were phenotypically normal (data not
shown). Litters that were born to parents that produced at
least one affected cat between November 1999 and April
2002 were included in the study (Table 1). None of the
affected kittens reached reproductive age. Cats were con-
sidered phenotypically affected when they exhibited typical
clinical signs and had high serum lysosomal enzyme levels
(see below). A total of 26 litters with 89 kittens were born to
phenotypically healthy parents. There were 10 male and 9
female kittens that were affected among 14 litters with 63
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kittens and at least 1 affected cat (Figure 1). A total of 7
kittens were stillborn (4 among the 63) and 1 kitten had no
serum lysosomal enzymes determined. These eight kittens
were excluded from further analysis. The proportion of
affected kittens was 23.4%.
There were no affected kittens out of 89 in 12 litters
generated from outcrossing parents that produced affected
cats with normal unrelated cats, thus excluding a dominant
mode of inheritance. Both genders were affected, which
ruled out an X-linked recessive mode of inheritance. The
affected kittens were siblings of phenotypically normal cats
and were born to phenotypically normal parents. These
findings support an autosomal recessive mode of inheri-
tance. Although the population tested was biased by selecting
litters that were born to parents that produced at least
one affected cat, the 23.4% of affected cats is very close to
the 25% expected for an autosomal recessive mode of
inheritance. Chi-square analysis was 0.012 (P . .05; one
degree of freedom), which supports the null hypothesis that
the number of affected kittens observed was not different
from the expected number of affected kittens for an
autosomal recessive mode of inheritance.
Biochemical Studies
Adult Cats
Because affected cats died or were euthanized before
adulthood, serum activities of a-mannosidase, b-glucuron-
idase, and a-fucosidase were only determined in phenotyp-
ically normal adult cats that produced affected kittens, as well
as normal unrelated controls. Serum enzyme activities from
nine obligate carriers (including male 3739) and eight
phenotypically normal unrelated healthy adult cats were
measured (Table 2). All obligate heterozygotes had clearly
higher serum lysosomal enzyme activities, ranging from two
to three times normal. Thus a determination of a-
mannosidase, b-glucuronidase, and a-fucosidase activity in
serum with appropriate controls could readily differentiate
carriers from normal adults. However, when the serum
activities from adult cats were compared to those in kittens
(see below), the range for the obligate carriers was markedly
lower in the adults.
Neonatal Kittens (Less Than 1 Week)
Neonatal kittens were classified phenotypically based on the
presence or absence of typical clinical signs until their death
(see below). Serum lysosomal enzyme activities from 59 of
63 neonatal kittens of the 14 litters having at least one
affected kitten were measured (4 were stillborn). Serum
lysosomal activities from affected kittens were many-fold
higher (11–73 times normal adult control) than activities of
phenotypically normal littermates (Table 3), supporting the
diagnosis of ML II. This study did not follow phenotypically
normal kittens to adulthood and most of them were not
used for breeding and enzyme analyses. Therefore their
genotype could not be definitively determined. However, if
one categorized phenotypically normal kittens into a group
having at least two of the three measured enzymes increased
by more than 1.5- but less than 6-fold above the mean of
normal adult cats, 24 kittens were defined as heterozygotes
and 16 as homozygous normal. Although the population
tested was biased toward affected kittens, out of these 59
neonatal kittens the proportions of affected (32%), carrier
(41%), and normal kittens (27%) were not statistically
different from a 1:2:1 ratio and thus consistent with an
autosomal recessive trait.
Microscopic examination of fibroblast cultures from
kittens affected with ML II had multiple cytoplasmic
granules approximately 10 lm in diameter (Figure 2),
whereas fibroblasts from phenotypically normal relatives
and unrelated healthy cats did not have inclusions. The
activities of a-mannosidase, b-glucuronidase, and a-fucosi-
dase were measured and were found to be reduced in
fibroblasts from affected kittens as compared to normal cats
(Table 4). The mean b-glucuronidase activity in affected
fibroblasts was the highest, at 56% of normal, while the mean
a-mannosidase activity with 9% of normal activity was the
lowest.
Clinical Findings
Initial clinical features in affected kittens included failure to
thrive and facial dysmorphism. Kittens with ML II had
similar birth weights when compared to normal littermates,
Table 1. Breeding data of the phenotypically normal half
sibling (no. 3739) of the original cat with mucolipidosis II
Male/no. of females (generation)
Breeding
3739/
4 (F1)
F1
a/
2 (F1)
F2/
4 (F1)
F1/
1 (F3) Total
Litters
Total 13 5 7 1 26
With affected
kittensb 6 2 5 1 14
Without affected
kittens 7 3 2 0 12
Affected offspring
Total 6 4 8 1 19
Males 4 2 3 1 10
Females 2 2 5 0 9
Phenotypically normal offspringc
Total 35 5 20 3 63
Males 23 2 6 2 33
Females 12 3 14 1 30
Stillborn offspringd
Total 1 3 3 0 7
a F1, F2, F3 refer to first, second, and third generations of offspring of male
3739.
b Affected male and female kittens had characteristic clinical signs and high
serum lysosomal enzyme levels.
c Phenotypically normal kittens with lysosomal enzyme levels in the normal
or carrier range.
d Stillborn kittens with no clinical examination or enzyme diagnosis available.
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but experienced significant weight and growth retardation
that was evident by 3 months of age (Figure 3). Affected
kittens failed to thrive and died or were euthanized due to
disease progression between the first day of life and 216 days
(mean 47 days, median 10 days; Figure 4), whereas morbidity
and mortality in unaffected littermate kittens were negligible.
The affected cats appeared behaviorally dull and were
quieter and less playful than their littermates. They showed
poor muscle tone from the first week of life and developed
progressive hind limb ataxia. Facial abnormalities present at
birth included thickened eyelids, hypertelorism (wide-spaced
eyes), frontal bossing, a depressed nasal bridge, and low-set
ears (Figure 5). In addition, affected kittens had congenital
carpal varus or valgus deformities, which became more
pronounced as the cats grew.
Five affected kittens were auscultated by a board-
certified cardiologist. Three of these kittens had normal
heart sounds, while two kittens had continuous, machinery
murmurs (grade 2/5) auscultated at the left and right heart
base. Several affected kittens developed upper respiratory
tract infections, whereas normal littermates did not. Four
other affected cats developed pleural and peritoneal tran-
sudates in their terminal stages, one of them also developed
a pericardial transudate. Thoracic and abdominal radio-
graphs appeared normal, except for cardiomegaly and
pleural effusions that developed as end-stage changes.
Echocardiographic evaluations were performed in five of
the affected kittens. Three kittens had mild to moderate
cardiomegaly in an eccentric pattern with Doppler-detected
continuous flow in the main pulmonary artery (although two
of them had ascultatable murmurs). No significant abnor-
malities were detected in the other two kittens evaluated by
echocardiography, although the left atrium appeared mildly
enlarged in one.
Figure 1. Pedigree of the cat family with mucolipidosis II. Litters with at least one affected ML II cat born to pheno-
typically normal parents between November 1999 and April 2002. The data from the litters with no affected kittens are not shown.
Females are circles, males squares; affected are filled circles and squares, stillborn have a cross, and the propositus has an
arrow. Affected kittens were offspring of phenotypically normal parents, they had phenotypically normal siblings, and both
sexes were affected (47% females, 53% males). No affected kittens were born from outcrossing parents of an affected animal
with normal unrelated cats. These findings are consistent with an autosomal recessive mode of inheritance.
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Complete blood cell counts, serum chemistry values, and
urinalyses of affected kittens were normal, except for a mild
neutrophilia compared to healthy normal kittens and pre-
viously published values (Meyers-Wallen et al. 1984). The
urine MPS spot test was slightly positive in three of seven
affected kittens tested.
Radiographic abnormalities of the skeleton were noticed
at an early age. Radial and ulnar bowing were evident by the
first month of life (Figure 6A). Delayed mineralization of the
femoral and tibial epiphyses was noticed by the second week
of life (Figure 6B,C), but resolved by 2.5 months of age.
Metaphyseal flaring occurred at 1 month of age. By 3 months
of life, coxofemoral joint laxity and luxation of the
antebrachial-carpal joints were seen (Figure 6A). Cervical
vertebral fusion occurred between the fourth and fifth
month of life (Figure 6D), and the lumbar vertebral bodies
fused shortly thereafter. The vertebral bodies were short, and
the dorsal spinal processes were misshapen. Other skeletal
abnormalities such as spina bifida and hemivertebrae were
observed in a few affected kittens.
On ophthalmologic examination of four affected cats
followed from birth to death, absent menace and decreased
pupillary light reflexes with no corneal changes were noticed
after the third month of life. At 4 months of age, the pupils
remained dilated in ambient light. Retinal development
initially appeared normal, but at 2.5 months of age thinning
of the dorsal retina venule and altered tapetal reflectivity
were noticed (Figure 7). These fundic abnormalities pro-
gressed to end-stage retinal degeneration and blindness by
3.5 months of age, with optic disc pallor, marked attenuation
of the retinal vessels, and tapetal hyperreflectivity (Figure 7).
As mentioned above, affected cats died naturally or were
euthanized in end-stage disease. Other than the small stature
and skeletal abnormalities, gross pathologic findings included
bronchopneumonia (n ¼ 1) and pleural, peritoneal, and
pericardial effusions (n ¼ 4). Cardiomegaly was noticed in
two of four affected kittens that survived longer than 3
months. Histopathologic findings and biochemical analysis
of tissues for enzymes and storage material will be reported
elsewhere.
Discussion
Thus far, more than 40 LSDs have been described in
humans, and for 21 of these, naturally occurring animal
models have been reported. Of these 21, 13 have been
described in cats (Haskins and Giger 1997; Haskins et al.
2002). ML II, first described as I-cell disease in humans in
1967 (Leroy and DeMars 1967), has been reported in
approximately 50 patients, with a prevalence of 0.16 per
100,000 births (Poorthuis et al. 1999) and remains a rare,
unique LSD that has not been completely characterized.
After the initial description of one cat with ML II (Bosshard
et al. 1996; Hubler et al. 1996), we describe here the
establishment of a colony of cats with ML II and demon-
strate its degree of homology to the disorder in humans.
A diagnosis of ML II in humans is made based on
clinicopathologic findings (Leroy et al. 1971), the character-
istic inclusions in fibroblasts (i.e., I-cells) (Leroy and DeMars
1967), with a secondary deficiency of fibroblast lysosomal
enzyme activities (Sprigz et al. 1978; Taber et al. 1973;
Whelan et al. 1983), and high activities of lysosomal enzymes
in serum or plasma and cell culture media (Sprigz et al. 1978;
Table 2. Mean lysosomal enzyme activities (6 SD) in serum
from adult obligate heterozygote cats for mucolipidosis II
and normal unrelated cats
Lysosomal enzyme
Obligate carrier
cats (n = 9)
Normal unrelated
cats (n = 8)
a-mannosidase,
nmol/h/ml 30,071 6 6,340 10,564 6 3,686
Percentagea 244 6 53 95 6 55
b-glucuronidase,
nmol/h/ml 778 6 326 265 6 107
Percentagea 285 6 162 96 6 47
a-fucosidase,
nmol/h/ml 454 6 114 195 6 67
Percentagea 218 6 63 101 6 51
SD ¼ standard deviation.
a Percentage of normal control activity in samples run simultaneously.
Table 3. Mean lysosomal enzyme activities (6 SD) in seruma from kittens with mucolipidosis II and phenotypically normal
littermate and unrelated kittens
Lysosomal enzyme
Affected kittens
(n = 19)
Phenotypically normal littermate
kittensb (n = 40)
Normal healthy unrelated
kittens (n = 5)
a-mannosidase, nmol/h/ml 63,636 6 26,185 13,590 6 9,802 8,875 6 1,609
Percentagec 1,180 6 346 246 6 136 122 6 22
b-glucuronidase, nmol/h/ml 9,239 6 2,910 670 6 775 144 6 80
Percentagec 7,369 6 3,048 544 6 678 84 6 47
a-fucosidase, nmol/h/ml 3,003 6 1,299 730 6 773 128 6 25
Percentagec 2,576 6 972 876 6 1,074 269 6 53
SD ¼ standard deviation.
a Serum samples taken at less than 1 week of age.
b Data includes heterozygote and normal kittens.
c Percentage of normal adult control activity run simultaneously.
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Whelan et al. 1983). A deficiency of GlcNAc-phosphotrans-
ferase activity in fibroblasts and other organs can be
demonstrated (Hasilik et al. 1981). The enzyme GlcNAc-
phosphotransferase is a large multimeric protein with three
subunits produced by two genes. One gene codes the a and b
subunits with 21 exons spanning 92 kb and is located on
human chromosome 12. The coding region for the c subunit
is on chromosome 16 (Canfield et al. 1998). However, the
sequence of the GlcNAc-phosphotransferase genes and
mutations causing ML II in humans has not been published
(Canfield et al. 1998 and personal communication). This
sequence information will permit the further molecular
characterization of ML II in cats.
Fibroblasts from affected kittens contained the charac-
teristic inclusions, which appeared identical to those seen in
humans (Hanai et al. 1971; Leroy and DeMars 1967). The
content of these inclusions has not been fully characterized
but appears not to be GAGs or lipids (Hanai et al. 1971).
Although the GlcNAc-phosphotransferase activity was
measured in the related affected cat, but not in animals
described here, affected kittens had extraordinarily high
serum activity of the measured lysosomal enzymes; similar
increases have been reported in human patients (Weismann
et al. 1971). Furthermore, these enzyme activities were
diminished in fibroblasts from affected kittens. The residual
enzyme activities in fibroblasts may be due to passive leakage
Figure 2. I-cells: Cytoplasmic inclusion bodies in fibroblasts of a kitten with mucolipidosis II. Multiple cytoplasmic granules
(arrows) approximately 10 lm in diameter in fibroblasts cultured from an affected kitten shown at 1003 magnification. N ¼
nucleus.
Table 4. Mean lysosomal enzyme activities (6 SD) in
fibroblasts from kittens with mucolipidosis II and normal
unrelated control cats
Affected cats
(n = 7)
Normal cats
(n = 3)
a-mannosidase, nmol/h/mg 41 6 21 479 6 156
Percentagea 9 6 4
b-glucuronidase, nmol/h/mg 308 6 51 555 6 45
Percentagea 56 6 9
a-fucosidase, nmol/h/mg 32 6 44 280 6 131.1
Percentagea 11 6 15
SD ¼ standard deviation.
a Percentage of the mean of normal activity.
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from the cell culture medium or to alternative mechanisms
for trafficking enzymes to the lysosome and may be cell type
specific (Dittmer et al. 1999; Glickman and Kornfeld 1993).
Thus residual activity of lysosomal enzymes in tissue may
explain why humans and cats affected with ML II do not
show storage and urinary excretion of many lysosomal
substrates such as GAG. The urine MPS spot test was
slightly positive in three of seven affected kittens tested,
however, this is a common finding in young animals.
Family studies in humans with ML II have been limited.
One report described 21 patients in 18 families (Okada et al.
1985), while others were case reports of one to eight patients.
Based on these studies, ML II in humans is thought to be an
autosomal recessive disease (Kornfeld and Sly 2000; Leroy
et al. 1971; Taber et al. 1973). The breeding studies reported
here of the male half sibling of the original domestic
shorthair cat with ML II clearly demonstrated an autosomal
recessive mode of inheritance. Approximately one-quarter of
all kittens were affected, with an equal number of both
genders born to phenotypically normal related parents, but
no affected kittens were born from outcrossings to unrelated
cats. Parents of affected kittens had moderately increased
serum activity of several lysosomal enzymes. Similarly
parents of one child with ML II were studied and
demonstrated a twofold increase in serum lysosomal enzyme
activities (Weismann et al. 1971). The increase in these
enzymes in obligate carriers suggests that the partial
deficiency of GlcNAc-phosphotransferase activity leads to
enzyme leakage into plasma, which allowed the identification
of heterozygotes in this family of cats. However, this partial
defect did not result in any clinical abnormalities in
heterozygotes.
As in human patients with ML II (Beck et al. 1995; Sprigz
et al. 1978), clinical signs in cats can be recognized within the
neonatal period and there is some clinical variability between
individuals. The facial and skeletal morphologic changes are
characteristic of MPS, but are generally not specific for
a particular type of MPS. Radiologic features of ML II in
children includes claw hands, pes valgus, short metacarpals,
coarse trabecular pattern of the long and short bones,
coxofemoral and shoulder dislocation, lumbar scoliosis,
inferior vertebral body beaking, dysostosis multiplex, diffuse
mineralization, osteopenia with periosteal diaphyseal new
bone formation, and pathologic fractures (Patriquin et al.
1977; Sprigz et al. 1978; Whelan et al. 1983). These changes
occur earlier in life than with other mucolipidoses (Taber
et al. 1973). The kittens affected with ML II demonstrated
very similar radiologic signs, which were present in the first
month of life and progressed rapidly. It appears likely that
the skeletal abnormalities are caused by deficient activity of
lysosomal enzymes relative to substrate load in bones and
cartilage, resulting in severe storage, as demonstrated in
chondrocytes (Bosshard et al. 1996).
The psychomotor development in affected children does
not proceed beyond 6–9 months of age and death occurs in
the first decade of life (Kornfeld and Sly 2000; Okada et al.
1985; Taber et al. 1973). Similarly the cats with ML II
appeared behaviorally dull and failed to thrive. To the best of
our knowledge, lesions have not been documented in the
brain of affected human patients, although inclusions in the
cerebral cortical neurons were reported in the original ML II
affected cat (Bosshard et al. 1996).
Corneal storage has not generally been appreciated in
human patients (Okada et al. 1985; Sprigz et al. 1978; Taber
et al. 1973; Whelan et al. 1983) or cats with ML II, except for
a couple of human patients (Libert et al. 1977). However, the
Figure 3. Body weight in grams from birth to 6 months of
kittens with mucolipidosis II and unaffected littermates.
Affected kittens had similar birth weights when compared to
normal littermates but experienced significant retardation
evident after 2 months of age. Circles represent ML II affected,
squares represent phenotypically normal littermates. (*P , .05,
single-factor ANOVA between 3 and 5 months).
Figure 4. Survival of 15 cats with mucolipidosis II. Survival
of 15 affected kittens that died or were euthanized with
end-stage disease: 11 of these cats died or were euthanized
before 3 weeks of age and all were dead by 7 months of age,
with the longest survival being 216 days (mean 47 days, median
10 days). Four affected kittens euthanized for eye histology
before end-stage disease have been excluded.
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Figure 6. Radiographic findings of kittens with mucolipidosis II. (A) Radial and ulnar bowing and luxation of the antebrachial-
carpal joint in a 6-month-old affected cat. (B) Delayed mineralization of the femoral head, distal femur, and proximal tibia in an
affected cat compared to (C) his control littermate, both at 1 month of age. (D) Cervical vertebrae of a 6-month-old affected
cat. The vertebral bodies are shortened and the dorsal spinal processes are misshapen. (Arrows point to all abnormalities.)
Figure 5. Facial abnormalities of kittens with mucolipidosis II were present early, including (A) thickened eyelids, wide-
spaced eyes (hypertelorism), and a flat, broad face, as well as (B) frontal bossing, depressed nasal bridge, and low-set ears.
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affected kittens studied developed progressive retinal de-
generation resulting in blindness by a few months of age,
which does not appear to be a typical feature of the human
disease. Only one human patient with retinal degeneration
has been reported (Okada et al. 1985); however, ophthal-
mologic studies of human patients are limited. The cause of
the photoreceptor degeneration is unclear. Because of the
trafficking defect, essential enzymes, such as proteases, may
be functionally absent in the lysosomes, resulting in
rhodopsin accumulation, which would lead to retinal
degeneration. Of interest is that humans with ML III
(Trabousi and Maumenee 1986) and some MPS disorders
develop retinal abnormalities.
As in affected kittens, ML II in human patients is rapidly
progressive. The causes of death in the first decade of life
have not always been determined, but some children die due
to heart failure exacerbated by pneumonia (Kornfeld and Sly
2000; Okada et al. 1985). Likewise, some kittens affected
with ML II developed upper respiratory infections and
cardiac failure; others died suddenly without an identifiable
cause. Systolic murmurs (Okada et al. 1985; Sprigz et al.
1978), cardiomegaly, in particular left ventricular enlarge-
ment on chest radiographs (Satoh et al. 1983; Sprigz et al.
1978), cardiomyopathy (Muller et al. 2000), and congenital
cardiac anomalies such as dextrocardia and mitral valve
prolapse accompanied by a prolong QT interval (Satoh et al.
1983) have been described in human patients. Pathology
reports in ML II-affected children have revealed heart failure
due to aortic regurgitation (Tang et al. 1995) and storage
of foam cells in the myocytes with thickened heart valves
(Satoh et al. 1983). The presence of cardiomegaly, thoracic
transudates, and pansystolic heart murmurs in affected
kittens was consistent with heart failure.
Therapy for most LSDs involves providing the enzyme
deficient in activity by intravenous injection of purified
enzyme, heterologous tissue transplantation (which acts to
make and secrete normal enzyme), or correcting autologous
cells by gene therapy. In ML II, the enzyme that is deficient in
activity is in the Golgi apparatus and would require gene
therapy of many cell types to correct the primary defect.
However, the clinical signs of ML II are the result of
trafficking failures of several distinct lysosomal enzymes. As
different enzymes may be responsible for the clinical signs
due to storage of various substrates in different tissues, the
most promising therapeutic approach would be heterologous
tissue transplantation (such as bone marrow) that would
secrete a variety of normal lysosomal enzymes for uptake by
different tissues. A recent report of bone marrow trans-
plantation in three children younger than 1.5 years appeared
to transiently slow disease progression (Peters et al. 2002).
Thus far this approach in two 1-month-oldML II kittens does
not appear to be helpful (Haskins et al., unpublished data).
In conclusion, this colony of cats is currently the only
animal model of human ML II. As in children with ML II,
affected kittens had early onset and progressive disease, with
similarly characteristic clinical signs, a short life span,
abnormal biochemical findings, and an autosomal recessive
mode of inheritance. Future investigation will define the
histopathologic lesions and the molecular basis of ML II in
cats. The close homology of the disease in these two species
indicates that cats with ML II will be a suitable model for the
investigation of the pathophysiology of ML II and the
Figure 7. Retinal changes of kittens with mucolipidosis II. (A) A normal control retina compared to (B) the retina of an
affected cat at 2.5 months of age, with notable thinning of retinal venules (arrows), and (C) the retina of an affected cat at 5
months of age with signs of diffuse retinal degeneration, including tapetal hyperreflectivity and vascular attenuation (arrows).
The optic disc is dark due to a photographic effect.
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for this unique lysosomal storage disease.
Acknowledgments
The authors thank Margret L. Casal, N. Matthew Ellinwood, Marc Kraus,
Katia Marioni, John R. Melniczek, Nuala J. Summerfield, Patricia O’Donnell,
Thomas M. O’Malley, Ulana Prociuk, Margaret A. Weil, Jean Zweigle,
veterinary students, and the ULAR staff for advice and assistance with the
animal colony. This research was supported in part by grants RR 02512 and
EY-13132 from the National Institutes of Health and by grant support from
the National MPS Society, Inc. This article was presented in part at the
American College of Veterinary Internal Medicine Forum, Dallas, TX, June
5, 2002, and at the Advances in Canine and Feline Genomics symposium, St.
Louis, MO, May 16–19, 2002.
References
Beck M, Barone R, Hoffmann R, Kratzer W, Radowsky T, Ngro F, and
Fiumara A, 1995. Inter- and intrafamilial variability in mucolipidosis II (I-
cell disease). Clin Genet 47:191–199.
Berry HK and Spinanger J, 1960. A paper spot test useful in study of
Hurler’s syndrome. J Lab Clin Med 55:136–138.
Bosshard NU, Hubler M, Arnold S, Briner J, Spycher MA, Sommerlade HJ,
von Figura K, and Gitzelmann R, 1996. Spontaneous mucolipidosis in a cat:
an animal model of human I-cell disease. Vet Pathol 33:1–13.
Canfield WM, Bao M, Pan J, Brewer AD, Pan H, Roe B, and Raas-
Rothschild A, 1998. Mucolipidosis II and mucolipidosis IIIA are caused by
mutations in the GlcNac-phosphotransferase a/b gene on chromosome
12p. Am J Hum Genet 63(suppl.):A15.
Dittmer FE, Ulbrich EJ, Hafner A, Schmahl W, Meister T, Pohlmann R,
and von Figura K, 1999. Alternative mechanisms for trafficking of
lysosomal enzymes in mannose 6-phosphate receptor-deficient mice are cell
type-specific. J Cell Sci 112:1591–1597.
Glaser JH and Sly WS, 1973. Beta-glucuronidase deficiency mucopolysac-
charidosis: methods for enzymatic diagnosis. J Lab Clin Med 82:969–
977.
Glickman JN and Kornfeld S, 1993. Mannose 6-phosphate-independent
targeting of lysosomal enzymes in I-cell disease B lymphoblasts. J Cell Biol
123:99–108.
Hanai J, Leroy J, and O’Brien JS, 1971. Ultrastructure of cultured
fibroblasts in I-cell disease. Am J Dis Child 122:34–38.
Hasilik A, Waheed A, and van Figura K, 1981. Enzymatic phosphorylation
of lysosomal enzymes in the presence of UDP-N-acetylglucosamine.
Absence of the activity in I-cell fibroblasts. Biochem Biophys Res Commun
98:761–768.
Haskins ME, Casal M, Ellinwood NM, Melniczek J, Mazrier H, and Giger
U, 2002. Animal models for mucopolysaccharidoses disorders and their
clinical relevance. Acta Paediatr Suppl 439:88–97.
Haskins ME and Giger U, 1997. Lysosomal storage diseases. In: Clinical
biochemistry of domestic animals (Kaneko JJ, Harvey JW, Bruss ML, eds).
San Diego: Academic Press; 741–760.
Hubler M, Haskins ME, Arnold S, Kaser-Hotz B, Bosshard NU, Briner J,
Spycher MA, Gitzelmann R, Sommerlade HJ, and von Figura K, 1996.
Mucolipidosis type II in a domestic shorthair cat. J Small Anim Pract
37:435–441.
Kaufmann H, Kozlowski K, Maroteaux P, Silverman F, Spranger J, Langer
L, Lefebvre J, Sauvegrain J, and Scott CI, 1970. A nomenclature for
constitutional (intrinsic) diseases of bones. Ann Radiol 13:455–464.
Kornfeld S and Sly WS, 2000. I-cell disease and pseudo-hurler polydys-
trophy: disorders of lysosomal enzyme phosphorylation and localization. In:
The metabolic and molecular bases of inherited disease (Scriver et al., eds).
New York: McGraw-Hill Professional; 3469–3482.
Leroy JG and DeMars RI, 1967. Mutant enzymatic and cytological
phenotypes in cultured human fibroblasts. Science 157:804–806.
Leroy JG,DeMars RI, andOpitz JM, 1969. I-cell disease. In: First conference
on clinical delineation of birth defects, original articles series. New York: The
National Foundation Birth Defects Research Centers; V:174–185.
Leroy JG, Spranger JW, Feingold M, Opitz JM, and Crocker AC, 1971. I-
cell disease: a clinical picture. J Pediatr 79:360–365.
Libert J, Van Hoff F, Farriaux J, and Toussaint D, 1977. Ocular findings in
I-cell disease (mucolipidosis type II). Am J Ophthalmol 83:617–628.
Lightbody J, Wiesmann U, Hadorn B, and Herschkowitz N, 1971. I-cell
disease: multiple lysosomal-enzyme defect. Lancet 1:451.
Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ, 1951. Protein
measurement with the folin phenol reagent. J Biol Chem 193:265–275.
McKusick VA, 2000. Mendelian inheritance in man. Available at http://
www.ncbi.nlm.nih.gov/omim. Visited in 2003.
Meyers-Wallen VN, Haskins ME, and Patterson DF, 1984. Hematologic
values in healthy neonatal, weanling, and juvenile kittens. Am J Vet Res
45:1322–1327.
Muller P, Reichenbach H, Mockel A, and Buhrdel P, 2000. I-cell disease
complicated by unusual dilatative cardiomyopathy. J Inherited Metab Dis
23:514–516.
Okada S, Owada M, Sakiyama T, Yutaka T, and Ogawa M, 1985. I-cell
disease: clinical studies of 21 Japanese cases. Clin Genet 28:207–215.
Patriquin HB, Kaplan P, Kind HP, and Giedion A, 1977. Neonatal
mucolipidosis II (I-cell disease): clinical and radiologic features in three
cases. Am J Roentgenol 129:37–43.
Peters C, Grewal S, Orchard P, Krivit W, Davies S, Shapiro E, Ziegler R,
Charnas L, Lockman L, Dusenbery K, et al., 2002. Hematopoietic cell
transplantation (HCT) is effective treatment for mucolipidosis II (MLII)
and alpha-mannosidosis (MAN). Am J Hum Genet 71(suppl.):579.
Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely
S, Niezen-Koning KE, and van Diggelen OP, 1999. The frequency of
lysosomal storage diseases in The Netherlands. Hum Genet 105:151–156.
Satoh Y, Sakamoto K, Fujibayashi Y, Uchiyama T, Kajiwara N, and Hatano
M, 1983. Cardiac involvement in mucolipidosis. Importance of non-invasive
studies for detection of cardiac abnormalities. Jpn Heart J 24:149–159.
Sprigz RA, Doughty RA, Spackman TJ, Murnane MJ, Coates PM,
Koldovsky O, and Zackai EH, 1978. Neonatal presentation of I-cell
disease. J Pediatr 93:954–958.
Taber P, Gyepes MT, Philippart M, and Ling S, 1973. Roentgenographic
manifestations of Leroy’s I-cell disease. Am J Roentgenol Radium Ther
Nucl Med 118:213–221.
Tang X, Hinohara T, Kato S, Watanabe K, and Tsutsumi Y, 1995. I-cell
disease: report of an autopsy case. Tokai J Exp Clin Med 20:109–120.
Tondeur M, Vamos-Hurwitz E, Mockel-Pohl S, Dereume JP, Cremer N,
and Loeb H, 1971. Clinical, biochemical, and ultrastructural studies in a case
of chondrodystrophy presenting the I-cell phenotype in tissue culture. J
Pediatr 79:366–378.
Trabousi EI and Maumenee IH, 1986. Ophthalmologic findings in
mucolipidosis III (pseudo-Hurler polydystrophy). Am J Ophthalmol
102:592–597.
Verma RS and Babu A, 1995. Tissue culture techniques and chromosome
preparation. Skin and other tissues. In: Human chromosomes: principles
and techniques (Verma RS, ed). New York: McGraw-Hill; 27–29.
Waheed A, Pohlmann R, Hasilik A, von Figura K, van Elsen A, and Leroy
JG, 1982. Deficiency of UDP-N-acetylglucosamine: lysosomal enzyme
372
Journal of Heredity 2003:94(5)
N-acetylglucosamine-1-phosphotransferase in organs of I-cell patients.
Biochem Biophys Res Commun 105:1052–1058.
Wegner DA and Williams C, 1991. Screening for lysosomal disorders. In:
Techniques in diagnostic human biochemical genetics: a laboratory manual
(Hommes FA, ed). New York: Wiley-Liss; 587–617.
Weismann U, Vassella F, and Herschkowitz N, 1971. I-cell disease: leakage
of lysosomal enzymes into extracellular fluids. N Engl J Med 285:1090–
1091.
Whelan DT, Chang PL, and Cockshott PW, 1983. Mucolipidosis II. The
clinical, radiological and biochemical features in three cases. Clin Genet
24:90–96.
Received February 14, 2003
Accepted June 17, 2003
Corresponding Editor: Elaine Ostrander
373
Mazrier et al.  Feline Mucolipidosis II
